MIB Agents OsteoBites
Ann Graham
Subscribe
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
Available episodes
Newest first
Oldest first
6 days ago
osTEAo Tea Spill: AYA Cancer Gab Sesh
Listen in this month as Mia and Sloane have a gab sesh about the daily interactions and challenges as an AYA living with cancer that get under their skin. Hear their thoughts on why there is a lot of room for improvement on Hollywood's representation of pediatric cancer patients, how cancer limits participation in a society that doesn't address the needs of people with disabilities, the difficulties around sharing their cancer story, the cliche of being brave, and why they wish there was an off button for snapchat memories.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Sep 15, 2023
Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques
Dr. Fiona Freeman is an Assistant Professor in the School of Mechanical and Materials Engineering at University College Dublin (UCD). She graduated in Biomedical Engineering in 2011 and earned her PhD from the University of Galway in 2016, focusing on developing new strategies for bone tissue regeneration. Afterward, Dr. Freeman was awarded two prestigious postdoctoral fellowships: the Government of Ireland IRC Postdoctoral Research Fellowship and the Marie Skłodowska-Curie Global Fellowship. These fellowships provided her with opportunities to work as a postdoctoral researcher in renowned labs at Massachusetts Institute of Technology (MIT), Brigham and Women's Hospital, Johns Hopkins University, and Trinity College Dublin.
In September 2022, Dr. Freeman was appointed as the first Ad Astra fellow in the School of Mechanical and Materials Engineering. Her current research focuses on using innovative engineering techniques to gain a better understanding of and develop novel therapeutics for treating osteosarcoma, a paediatric bone cancer. As part of her research, Dr. Freeman identified a novel microRNA, miR-29b, as a potential therapeutic target for osteosarcoma. She formulated miR-29b nanoparticles and delivered the miRNA to the tumour site using a hyaluronic-based hydrogel delivery system. The results showed a significant decrease in tumour burden, increased survival rates, and enhanced regeneration of the damaged bone surrounding the tumour.
These findings have the potential to revolutionize osteosarcoma treatment and improve patient outcomes by significantly reducing the primary tumour mass and providing crucial data that will inform the design of future therapies for young patients. Dr. Freeman conducted this work in collaboration with researchers at MIT and Brigham and Women's Hospital. In the coming years, Dr. Freeman is dedicated to building upon this research and advancing this technology toward clinical application.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Sep 1, 2023
Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma
This episode is sponsored is by BTG Pharmaceuticals
Dr. Michael Bishop is an Assistant Member in the Solid Tumor Division of the Department of Oncology at St. Jude Children’s Hospital in Memphis, TN. His clinical practice focuses primarily on the management of children and young adults with bone and soft tissue sarcomas, and his research interests are dedicated to the development of prospective clinical trials for the treatment of osteosarcoma. Dr. Bishop graduated from the University of Arkansas College of Medicine and completed his pediatric residency at Children’s Mercy Kansas City, and fellowship in pediatric hematology and oncology at Cincinnati Children’s Hospital Medical Center. Dr. Bishop is a member of the Children’s Oncology Group Bone Tumor Committee and is the Study Chair for AOST2032, a prospective trial assessing the feasibility and efficacy of combining a multi-targeted tyrosine kinase inhibitor with chemotherapy for newly diagnosed osteosarcoma.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Aug 25, 2023
Immune Therapies in EGFR-Expressing Cancers
This presentation discusses key findings in immunotherapies from the investigator's laboratory as well as those that have shaped the landscape of both human and canine cancers. The information focuses on EGFR and HER2 based immunotherapies, including osteosarcoma, hemangiosarcoma and other cancer types in canine patients. Mechanisms of tumor growth and therapy will also be topics of discussions.
---
UCLA (B.A.), Univ Notre Dame (M.S.), University of Oklahoma Health Sciences Center (Ph.D.), Yale University School of Medicine (Professor of Medicine). Dr. Mamula’s interests are in investigating the early events of inflammatory mediated changes in the proteome that intersect with cellular metabolism and with breaking immune tolerance to self proteins. These studies have been applied to the development of novel immune-therapeutic approaches in for antitumor vaccines in EGFR/HER2 expressing cancers, including breast cancer and colon cancer. In particular, the work has evolved to clinical trials in companion canine populations. Overall, it is the goal of Dr. Mamula’s laboratory to understand the mechanisms that may shift the balance of the cellular proteome toward the initiation of anti-self immune responses. In addition, seminal work from the Mamula lab elucidated the proteomics and biochemical forms of autoantigens capable of breaking immunologic tolerance to intracellular autoantigens in type I diabetes (T1D) and in systemic lupus erythematosus (SLE). Simply put, Dr. Mamula examines post translational protein modifications that alter cellular biology and immunity. Recent studies have identified early protein modifications of pancreatic beta cells that are sentinels of early disease and dysfunction of glucose metabolism and insulin release (Nature Comm. 2022). Finally, studies from the Mamula laboratory first demonstrated the ability of B lymphocytes to present autoantigens in the triggering of T cell autoimmunity and in the phenomenon of epitope spreading in lupus autoimmunity, work that contributed to the rationale of B cell mediated therapeutics (Rituximab and Belumimab) in SLE. Dr. Mamula has 113 publications and has mentored over 30 pre-and postdoctoral students and investigators, many of whom have acquired faculty positions as independent investigators at major medical schools, universities, and pharmaceutical industries.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Aug 17, 2023
OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings
OsteoWarriors Camille and Mia are joined by members of the MIB Agents Junior Advisory Board to discuss questions submitted by patients, caregivers, clinicians, and researchers. This episode was inspired by the tremendous interest and engagement in the patient panel at the MIB Agents FACTOR 2023 osteosarcoma conference.
Camille, Mia, and our Junior Advisory Board discuss many topics including cancer misconceptions, the cringiest things you can say to someone with cancer, what makes them feel supported and seen in their journey by friends and loved ones, making decisions about surgical options, how they cope with scanxiety and preparing for a procedure, and what gets them through their hardest times.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Aug 11, 2023
Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms
Episode sponsored by BTG
Cancer is one of the leading causes of death worldwide. Significant efforts are still necessary to individuate new therapeutic strategies aimed to reduce cancer recurrence and to define new potential adjuvant targets for inhibiting invasion and metastasis, two significant contributors to death among patients. The increasing interest in the employment of nanostructured materials to medicine-related branches is attributable to its unique properties allowing highly efficient drug delivery, molecular sensing applicable in diagnosis, multiplex imaging, or construction of point of care therapeutic devices. This presentation will walk you through our latest developments of functional 3D dual-modality nanostructures for targeted drug delivery of platinum-based complexes.
Václav Ranc received his Ph.D. degree in analytical chemistry in 2009 from the Department of Analytical chemistry, Palacky University in Olomouc, Czech Republic under a supervision of Prof. Karel Lemr. He was then employed at the Department of Analytical chemistry, Palacky University, Olomouc as an assistant professor from 2008 to 2010. In 2011, he joined the team of prof. Rainer at the department of medicine at the University of Fribourg in Switzerland as a research scientist. He worked there from 2011-2012. He has been employed at the Regional center of advanced technologies and materials, Palacký University Olomouc since 2012. He has authored or co-authored 74 scientific publications, H index = 27. He is a co-author of three international patents. His research activities are directed towards development of nano-sensors based on the utilization of Surface enhanced Raman spectroscopy and electrochemistry, and synthesis of functionalized nanomaterials for drug delivery systems.
playlist_add
Aug 4, 2023
MIB Agents and SARC: A Case Study in Collaboration
Osteosarcoma Webinar Series: Scott Okuno, MD - SARC Medical Officer and Ann Graham, Executive Director of MIB Agents join us on OsteoBites to discuss how SARC (Sarcoma Alliance for Research through Collaboration) work together to drive collaboration in the sarcoma community and support sarcoma research.
--
Dr. Scott Okuno is Professor of Oncology at Mayo Clinic in Rochester, Minnesota. He is a recognized expert in sarcoma and clinical research. Dr. Okuno has been the SARC Medical Officer since 2012. In this role, he provides medical oversight to the day-to-day activities of the SARC clinical trials. Dr. Okuno regularly interacts with the SARC Research Project Management team and the study Principal Investigators to ensure proper study conduct, quality data and overall safety for all SARC clinical trials. Dr. Okuno was appointed SARC Chief Medical Officer in September 2022, and joined SARC Board of Directors October 2022.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Jul 28, 2023
OSI Funded Work
The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI’s Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI’s osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects.
Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute.
Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna’s research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute’s Strategic Advisory Board.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Jul 20, 2023
OsTEAo - Survivor's Guilt and Grief with grief coach Lori Krause
OsteoWarriors Camille and Gillian are joined by grief coach Lori Krause to discuss what survivor's grief and guilt look like and how to cope and learn to live with these feelings.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Jul 14, 2023
Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma
Dr. Jeffrey Bryan earned his D.V.M. from the University of California - Davis in 1993. He worked as an Associate Veterinarian from 1993-1995 and served as Medical Director from 1995-2002 of the Irving Street Veterinary Hospital in San Francisco, CA. Bryan then completed a medical oncology residency, a Masters of Biomedical Sciences, and a PhD in Pathobiology at the University of Missouri. He received certification by the American College of Veterinary Internal Medicine in Oncology 2005. He is the Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology, the Director of PET Imaging Center of the University of Missouri, Associate Department Chair for Research, and the Associate Director of Comparative Oncology for Ellis Fischel Cancer Center. Dr. Bryan’s research focuses on comparative examination of cancers in companion animals to better understand cancers in all species. His particular areas of interest are targeted imaging and therapy, epigenetics, and immunotherapy of cancers. He directs the PET Imaging Center, which seeks to develop novel PET imaging agents for cancer diagnosis, localization, and prognostication. He studies DNA methylation of canine non-Hodgkin lymphoma. He studies immunotherapy in companion dogs including investigating fetal microchimerism.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel
playlist_add
Jun 15, 2023
osTEAo - Coping with Humor: A Review of Cancer Memes
Mia and her special guest Jessie review and discuss cancer memes. Mia shares how these memes resonate with her real-life experiences, and Jessie offers perspective as a friend and partner to a cancer patient. If you are a cancer patient, you will likely laugh along and completely relate to these memes. For clinicians, friends, and family of a cancer patient, you will hear a frank (and funny!) discussion that will provide you insight into the cancer patient experience.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants…
playlist_add
Jun 9, 2023
The Importance of Patient-Powered Osteosarcoma Research: Count Me In
Dr. Katie Janeway, a pediatric hematologist-oncologist of Dana Farber/Boston's Children Hospital, and Benjamin Zola, a Project Manager at Count Me In (CMI), will be joining to share more insight into Count Me In's patient- powered Osteosarcoma research project, and the potential outcomes for discoveries that can have a direct impact on the future osteosarcoma.
Count Me In (CMI) is a nonprofit research initiative on a mission to make every patient's experience count in the effort to understand and overcome cancer. Founded in 2018 by Emerson Collective, Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute, Count Me In engages patients and enables them to accelerate cancer research by sharing their samples, clinical information, and voices. From their contributions, Count Me In analyzes and shares de-identified data freely to catalyze discoveries across cancer. Data generated by Count Me In is shared regularly via scientific platforms so that it can be harnessed by resear…
playlist_add
Jun 2, 2023
Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars
Dr. Alice Soragni, PhD, is an Assistant Professor in the David Geffen School of Medicine at UCLA, a member of the Jonsson Comprehensive Cancer Center and of the UCLA Molecular Biology Institute. She has a Master of Science cum Laude from the University of Bologna, Italy and a PhD from the ETH of Zuerich, Switzerland. Her laboratory in the Department of Orthopaedic Surgery at UCLA couples basic research into mechanisms of disease to the development of novel therapeutic strategies. The lab focuses on developing tumor organoid models to investigate the biology of rare tumors and to perform screenings for precision medicine applications.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and in…
playlist_add
May 26, 2023
Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases
Dr. Christian Capitini is an associate professor and the Jean R. Finley Professor of Pediatric Hematology and Oncology. He serves as co-leader of the Developmental Therapeutics Program at the University of Wisconsin Carbone Cancer Center and director of clinical innovation at the Forward BIO Institute. He has received many awards for his clinical and research contributions, including the Department of Pediatrics Gerard B. Odell Research Award, the Outstanding New Member Science Award from the Society for Pediatric Research (SPR), and the Janet Rowley Award from the Jonas Center Cellular Therapy Symposium at the University of Chicago. Nationally, Dr. Capitini is an active member of the Society for Immunotherapy of Cancer (SITC) and serves as at-large director. Additionally, he serves on the executive board for the Pediatric Real World chimeric antigen receptor (CAR) T Consortium.
Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based immunotherapies, inclu…
playlist_add
May 18, 2023
osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient
A cancer diagnosis can affect your ability to do the things you love, like sports, dance, and school, stripping your identity of your hobbies and passions. OsteoWarriors Camille and Mia chat about this loss of identity and how they cope.Listen in as they discuss what it's like dealing with a sense of loss of self and how they manage to form an identity outside of cancer.
---
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Bro…
playlist_add
May 12, 2023
OSI Connect: Osteosarcoma Answers and Assistance
OSI Connect is the Osteosarcoma Institute’s free, easy-to-use resource for patients who have been diagnosed with osteosarcoma or suffered a relapse after initial treatment. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chelsey Blanks, OSI Connect Administrator. You will learn how OSI Connect works and examples of how the program has helped more than 70 patients since its launch in 2019.
Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the Uni…
playlist_add
May 9, 2023
Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
*Please note : The safety and efficacy of GD2-SADA:177Lu-DOTA Drug Complex have not been established and have not been approved by health authorities in the US or globally.
Janet Yoon, M.D., specializes in pediatric hematology/oncology because it allows her to build long-term relationships with her young patients and their caregivers. Inspired by their resilience and strength, she stays at the leading edge of her field so that she can introduce families to the latest therapies, specifically those that minimize harmful and long-lasting side effects.
Dr. Yoon received her medical degree from the Medical College of Ohio and then served as a pediatric resident at the Medical University of South Carolina. She moved to California to pursue a pediatric hematology/oncology fellowship at Children’s Hospital Los Angeles. Prior to City of Hope, Dr. Yoon was at University of California Davis Medical Center then spent over a decade at University of California San Diego/Rady Children’s Hospita…
playlist_add
Apr 28, 2023
SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53
Bang H. Hoang, MD, is a board-certified orthopedic surgeon specializing in musculoskeletal tumor surgery. Dr. Hoang is an expert in benign and malignant tumors, metastatic bone disease, pathologic fractures, complex bone and joint reconstruction with large-segment prosthesis and allograft, tumors of the pelvis and sacrum, and investigational therapy for bone and soft tissue sarcoma. He is the Co-Director of the Orthopaedic Oncology Division at Montefiore and Professor of Orthopaedic Surgery at Albert Einstein College of Medicine.
--
What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Res…
playlist_add
Apr 20, 2023
osTEAo - Navigating Scanxiety
You are not alone - scanxiety is real! OsteoWarriors Camille and Mia chat about scans and share their experiences with the different types of scans, from x-rays to CT scans, to MRIs and PET scans. Listen in as they discuss what it's like adapting to life that is regularly punctuated with scans and share how they cope with scanxiety.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT…
playlist_add
Apr 14, 2023
Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?
Cristina Canal Barnils (Barcelona 1977) is Associate professor at the Department of Materials Science and Engineering, at the Technical University of Catalonia (UPC), head of the PlasmaMedLab: Plasmas for BioMedical Applications Laboratory and of the Medical Technologies: Biomaterials & Tissue Engineering research group at the IRSJD.
Before joining UPC, she did different research stages at pre and postdoctoral level in different national and international research centres. She has participated and lead a number of research projects, as well as technology transfer projects in the areas of Textile materials, Biomaterials and Cold Plasmas. Her research has led to above 60 publications, and several invited conferences. Her research has been recognized with different awards, including the L’Oreal-Unesco fellowship “For Young Women in Science” (2012), the “2018 Early Career Award in Plasma Medicine“ and the ICREA Acadèmia 2020.
Her interests are focused in cold plasmas for biome…
playlist_add
Mar 31, 2023
UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression
Dr. Claudia Benavente studied Molecular Biotechnology Engineering at Universidad de Chile where her interest in pursuing cancer research first started. To further her studies, she came to the US to pursue a doctoral degree in Cancer Biology at The University of Arizona as a Fulbright scholar. She then moved on as a postdoctoral fellow to St. Jude Children’s Research Hospital in Memphis, TN where she became familiar with childhood solid tumors. Professor Benavente is currently an Associate Professor at the Departments of Pharmaceutical Sciences and Developmental and Cell Biology and a member of the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Dr. Benavente’s research focuses on understanding how pediatric tumors form to design new ways to treat them. Her research aims to understand how genes are normally controlled in developing tissues and how epigenetic processes are perturbed to facilitate cancers to arise. This information guides her in the de…
playlist_add
Mar 24, 2023
Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma
Erin S. Murphy MD is an Associate Professor in the department of radiation oncology at the Cleveland Clinic. She completed residency at the Cleveland Clinic and a fellowship in pediatric radiation oncology at St. Jude Children’s Research Hospital. She specializes in radiotherapy and radiosurgery for brain tumors and pediatric tumors and is passionate about using aggressive local tools while maintaining quality of life for her patients.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS res…
playlist_add
Mar 16, 2023
osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives
OsteoWarriors Camille and Mia are joined by OsteoWarriors Daniel and Kara in this episode on navigating life and campus with limb salvage surgery and amputation, which are the primary treatment options to remove an osteosarcoma tumor. Listen in as they discuss why they chose limb salvage surgery or amputation and how they manage getting around school, and share challenges and horror stories they've experienced which are sure to make you both grimace and laugh.
---
Save the Date and mark your calendars for FACTOR 2023 - June 22-24 in Atlanta GA. Registration is now live! Go to MIBAgents.org to register.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with th…
playlist_add
Mar 10, 2023
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Dr. Kelly M. Bailey MD, PhD, is a pediatric oncologist certified by the American Board of Pediatrics. She is assistant professor of pediatrics at the University of Pittsburgh School of Medicine. Dr. Bailey received her medical degree and PhD from West Virginia University, Morgantown, W.Va., and completed her residency in pediatrics and fellowship in pediatric hematology/oncology at the University of Michigan School of Medicine, Ann Arbor, Mich. Dr. Bailey’s clinical and research interests focus on pediatric sarcomas, specifically Ewing sarcoma. Nationally, Dr. Bailey is active in the Children’s Oncology Group Bone Tumor Committee and the New Agents for Ewing Sarcoma Task Force.
Dr. Bailey’s studies the rare primary pediatric bone tumor Ewing sarcoma. Her research focuses on understanding the intersection of DNA damage and immunoregulation of this tumor.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents…
playlist_add
Mar 3, 2023
SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care
Surgery along with chemotherapy is the mainstay of treatment for patients with osteosarcoma. In order to achieve a cure, during surgery healthy tissue surrounding the tumour is also removed. Whilst this reduces the chances of the cancer returning, it can also result in added pain and disability for patients, impacting their quality of life in the longer-term. Advancements in surgical technology and technique offer the hope of improved outcomes for patients.
Recent developments have led to the introduction of fluorescence guided surgery (FGS), a technique which harnesses the emission of light to identify a tumour’s precise location and boundaries during surgical removal. This improves a surgeon’s ability to successfully remove the entire tumour, which can be identified as a ‘glowing’ area of tissue, decreasing the likelihood of any cancer cells remaining, while limiting the removal of too much healthy tissue.
This upcoming clinical trial, led by Kenneth Rankin, a leading Consu…
playlist_add
Feb 17, 2023
Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections
Jayanthi Parthasarathy BDS, MS, PhD, manages the 3D Printing Lab at Nationwide Children’s Hospital, which provides comprehensive patient-specific treatment planning and device development services from a pediatric perspective. She will discuss virtual surgical planning and 3D printing in pediatric musculoskeletal oncological resections.
A trained dental surgeon with more than 3 decades of practice, Dr. Parthasarathy is a pioneer in additive manufacturing for clinical needs, specializing in the development of patient-specific medical devices using advanced design and manufacturing technologies, having used the technology for more than 2 decades. With a masters in manufacturing and a doctorate in industrial engineering has researched on design and manufacturing of patient-specific devices using 3D printing and material composition for medical 3D printing. Dr. Parthsarathy worked in the medical device industry specializing in bringing to market patient-specific implantable and non-im…
playlist_add
Jan 27, 2023
Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response
Eunice Lopez Fuentes is in her postdoc studies at UCSF in Sweet-Cordero Lab. She is interested in defining the mechanisms of epigenetic gene regulation in osteosarcoma. Fuentes has uncovered two epigenetic different cell states with differential drug responses. Her main goal is to gain insight into the biology of these subclasses and define how their distinct master regulators may determine new clinically relevant vulnerabilities.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,0…
playlist_add
Jan 13, 2023
Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Marie Nelson, M.D., is originally from Michigan, attended college at the University of Notre Dame and earned her medical degree from Loyola University Chicago Stritch School of Medicine. She finished her residency in Pediatrics at Ann & Robert H. Lurie Children’s Hospital of Chicago prior to completing a fellowship in Pediatric Hematology, Oncology, and Bone Marrow Transplantation at Children’s National Hospital in Washington, D.C. Dr. Nelson is a member of the solid tumor faculty and Assistant Professor of Pediatrics at Children’s National Hospital where she also leads the Adolescent and Young Adult Oncology Program. Her research focuses on combining local therapies and immunotherapy in order to improve the outcomes and reduce the side effects of treatment for pediatric patients with solid tumors.
She is the principal investigator of a phase II trial combining cryoablation and immune checkpoint inhibitors in pediatric solid tumors.
---
What We Do at MIB Agents: PROGRAMS: ✨…
playlist_add
Dec 9, 2022
Cell Based Therapies for Osteosarcoma
Michael Leibowitz is an Assistant Professor in Hematology/Oncology/BMT and Cellular Therapeutics at Children's Hospital of Colorado. He is a physician-scientist whose research focuses on developing novel and effective cellular therapies for solid tumors including osteosarcoma.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids ar…
playlist_add
Nov 17, 2022
osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?
OsteoWarrior Mia and her mom Serena have a frank conversation with orthopedic oncologist and OsteoWarrior Dr. Kurt Weiss from the University of PIttsburgh. They discuss questions patients and caregivers often have about Ostesosarcoma but are afraid to ask.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with…
playlist_add
Nov 11, 2022
Interventional Radiology/HIFU Perspectives for Osteosarcoma
Karun V. Sharma, M.D., Ph.D., is the Director of Interventional Radiology at Children's National Hospital, and an Associate Professor of Pediatrics and Radiology at the George Washington University School of Medicine and Health Sciences. His clinical practice and translational research focuses on minimally invasive image-guided therapies for musculoskeletal and oncology conditions. Dr. Sharma leads the Image-Guided Non-Invasive Therapeutic Energy (IGNITE) program, a collaboration of the Sheikh Zayed Institute and the departments of Radiology, Oncology, Surgery, and Anesthesiology at Children’s National Hospital. The IGNITE program aims to improve the quality of life and outcomes for pediatric patients through the development and clinical translation of novel minimally invasive and noninvasive surgery technologies and combination therapy approaches, with the ultimate goal of making pediatric surgery more precise, less invasive and pain-free. In the recent years, Dr. Sharma and the I…
playlist_add
Nov 4, 2022
Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma
Dr. Dan Regan discusses his OutSmarting Osteosarcoma funded work on Focal Adhesion Kinase (FAK) inhibition to improve losartan-sunitinib immunotherapy in metastatic osteosarcoma.
-
Dr. Dan Regan is an Assistant Professor at the Flint Animal Cancer Center at Colorado State University and he is one of our OutSmarting Osteosarcoma 2022 grant recipients. Dr. Regan received his DVM degree from the University of Georgia and subsequently completed his residency training in veterinary anatomic pathology and PhD in the Department of Microbiology, Immunology, and Pathology (MIP) at Colorado State University. In 2018 he joined the Flint Animal Cancer Center and MIP in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. The focus of Dr. Regan’s laboratory is to increase our understanding of the interplay between the immune system and (non-immune) tumor stroma, and how these compartments of the tumor microenvironment promote metastasis as well as resp…
playlist_add
Oct 28, 2022
Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
---
Benjamin Nacev, MD PhD is a physician-scientist with an interest in sarcoma biology. His work focuses on understanding the causes of sarcomas with a goal of developing new treatments. Dr. Nacev completed his MD and PhD training at the Johns Hopkins University School of Medicine, where he also trained in Internal Medicine. He moved to Memorial Sloan Kettering where he completed his Medical Oncology Fellowship and later joined the faculty b…
playlist_add
Oct 20, 2022
osTEAo Presents Halloween Spooky Stories
Mia and Vicky talk about unexpected complications during their cancer journey and how they were able to cope, and what could’ve done to ease it beforehand in this raw, real conversation spilling the tea on osteosarcoma, and AYA cancer.
---
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatmen…
playlist_add
Oct 14, 2022
How Osteosarcoma Evolves from Diagnosis to Relapse
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
-
Dr. Kinnaman is current a member of the Pediatric Sarcoma Service at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in taking…
playlist_add
Oct 7, 2022
Transforming the Way Researchers Share Data: Lessons from the Pediatric Cancer Data Commons
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
---
Dr. Volchenboum is an associate professor of pediatrics and the associate chief research informatics officer for the biological sciences division at the University of Chicago. He is the Dean of Masters Programs, and he designed and launched the UChicago Master’s in Biomedical Informatics. His clinical specialty is pediatric hematology / oncology, caring for kids with cancer and blood diseases. His research group includes the University…
playlist_add
Sep 22, 2022
osTEAo - Dating & Intimacy with Lauren Broschak, MSW, LCSW, OSW-C
Lauren Broschak is an oncology-certified Licensed Clinical Social Worker who joined the Life with Cancer team in May 2019. She received her Master’s degree in social work from the University of Michigan, where she specialized in clinical practice and health. She provides therapeutic support, resources and education to patients and their caregivers. Lauren serves as the Co-Chair for the Association of Oncology Social Work Adolescent and Young Adult (AYA) Special Interest Group, and has spoken at national conferences regarding the impact of cancer on AYAs. She has completed training through the Enriching Communication Skills for Health Professionals in Oncofertility (ECHO) program, and is currently attending the University of Michigan’s Sexual Health Certificate Program specializing in sex therapy and sexuality education. Her areas of interest include AYAs impacted by cancer, illness’ effect on sexuality, intimacy and fertility, couples and cancer, dating and cancer, and caregiver…
playlist_add
Sep 16, 2022
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma
We would like to thank the sponsor of this episode, _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
---
Dr. Nancy DeMore is a board-certified breast surgical oncologist and is the BMW endowed chair in cancer research at MUSC Health. Dr. DeMore obtained her medical degree from Chicago Medical School. She completed her residency at Boston University Medical Center, a cancer research fellowship at Harvard Medical School, and fellowship training at Memorial S…
playlist_add
Sep 9, 2022
Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
---
Dr. Nathalie Gaspar, MD, PhD, is a pediatric oncologist at Gustave Roussy Cancer Campus (Villejuif, France), head of the adolescent and young ad…
playlist_add
Sep 2, 2022
Inhaled Recombinant Human IL-15 in Dogs with Naturally Occurring Pulmonary Metastases from Osteosarcoma or Melanoma: a Phase 1 Study
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
---
Dr. Canter is a Surgical Oncologist with clinical expertise in the multidisciplinary management of sarcomas. He also runs a translational research laboratory which focuses on the therapeutic and mechanistic effects of combining natural killer (NK) cell immunotherapy with other treatment modalities to overcome NK dysfunction in the tumor microenvironment of solid tumors, including sarcomas in both humans and dogs. He serves as the co-leade…
playlist_add
Aug 26, 2022
Outsmarting OS 2021 Funded Research Update: Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
---
Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and…
playlist_add
Aug 18, 2022
Back to School: OsteoWarrior and OsteoSibling Perspectives
Listen in on honest conversations as Osteosarcoma Warriors and survivors discusses all aspects of the young adult cancer experience in this brave and frank podcast.
--
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help…
playlist_add
Aug 12, 2022
Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma
Dr. Yustein is a pediatric oncologist and physician-scientist with significant training in molecular and cellular biology. During his time as the Director of the Faris D. Ewing Sarcoma Center at Texas Children's Hospital, he recognized the need for improving our understanding of the molecular pathogenesis of sarcomas and the identification of new therapeutic avenues, especially for patients with therapeutic resistant and/or metastatic disease. His laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development/resistance and metastatic progression and translating these findings towards testing novel therapeutic interventions for these aggressive malignancies. His laboratory has developed and characterized robust metastatic genetically engineered mouse models (GEMM) for pediatric sarcomas, including osteosarcoma (OS), which recapitulate the human disease initiati…
playlist_add
Aug 5, 2022
Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
--
John A. Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. Dr. Ligon earned h…
playlist_add
Jul 29, 2022
COG Project: Every Child - Episode Sponsored by Osteosarcoma Institute
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
A pediatric oncologist and physician-scientist, Dr. Crompton is the Research Co-Director of the Solid Tumor Center at Dana-Farber/Boston Children’s…
playlist_add
Jul 21, 2022
Body Image for AYAs with Cancer with Dr. Lori Weiner
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨
playlist_add
Jul 15, 2022
Unanswered Clinical Questions in Sarcoma: Opportunities to Move from Bedside to Bench - Episode Sponsored by Osteosarcoma Institute
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
Dr. Chris Collier is a dedicated surgeon-scientist who leads innovative basic science and clinical research to improve outcomes for his patients. He…
playlist_add
Jul 10, 2022
Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer - Episode Sponsored by Osteosarcoma Institute
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
Join us for OsteoBites with Dr. Alanna Church from Boston Children's Hospital. She will discuss the study recently published in Nature Medicine with…
playlist_add
Jun 20, 2022
Navigating Pediatric Cancer Clinical Trials
Learn more about the clinical trial process, tips for finding all possible trials, and considerations when choosing a trial.
Brenna Carswell, a childhood cancer survivor and mother of two, holds a Master's degree in Counseling Psychology. Although oncology has been a key part of her life for over 30 years, she has worked directly with patients, families, researchers, and clinicians for the last 8 years. Along with pediatric cancer research and trials, Brenna is passionate about humanitarian causes and child welfare. She makes time for fun and escapes to the beach with her daughters as often as possible.
What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought…
playlist_add
Jun 10, 2022
Update on OSI funded phase 2 Trial of Olaparib + Ceralasertib in Recurrent Osteosarcoma
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
Dr. Janeway received her medical degree from Harvard Medical School in 2000. She subsequently completed her residency in Pediatrics at Children's Hospit…
playlist_add
May 27, 2022
Limb Salvage Surgery for OS: Patient & Surgeon Perspectives sponsored by the Osteosarcoma Institute
This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions.
Dr. John Healey, Chief, Orthopaedic Service; Stephen McDermott Chair in Surgery, is an orthopaedic surgeon who specializes in caring for people with…
playlist_add
May 20, 2022
"Armored" CAR T cells for Osteosarcoma sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
This session focuses on a Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal.
Dr. Bilal Omer is a physician at Texas Children’s Cancer Center. In 2013, he completed his fellowship training in pediatric hematology-oncology. Dr. Omer is a member of the Bone Marrow Transplant (BMT)/Stem Celll Transplant Program and Medical Director at the Center for Cell a…
playlist_add
May 13, 2022
Immunotherapy for Osteosarcoma - Where Do We Go From Here? Sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
Dr. Breelyn A. Wilky, MD is a sarcoma medical oncologist and clinical trialist with research interests in immunotherapy, targeted therapy and precision medicine, and early phase drug development. She is Associate Professor and Director of the Sarcoma Program at the University of Colorado School of Medicine, and is a member of the Phase One and Experimental Molecular Therapeutics (…
playlist_add
May 6, 2022
The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage…
playlist_add
Apr 29, 2022
osTEAo Debut
Camille, Mia, Carrigan, Vicky chat about what's it like in this raw, real conversation spilling the tea on osteosarcoma, and AYA cancer.
playlist_add
Apr 22, 2022
Update on Clinical Trial Development Targeting Tumor Microenvironment in Refractory and Metastatic Osteosarcoma
Dr. Huang is the Director of Center for Pediatric Immunotherapy in the Angie Fowler AYA Cancer Institute at UH Rainbow Babies & Children's Hospital, Professor of Pediatrics at Case Western Reserve University School of Medicine, and co-leader of Immune Oncology Program at Case Comprehensive Cancer Center. He also directs the Pediatric Hematology-Oncology Fellowship Program at UH Rainbow. Dr. VanHeyst is an Assistant Professor of Pediatrics at Angie Fowler AYA Cancer Institute at UH Rainbow Babies & Children's Hospital and Case Western Reserve University School of Medicine. Dr. VanHeyst has worked closely with Dr. Huang to bring a myriad of clinical trial options as direct translations from bench research to the bedside, including newly opened Phase I clinical trial using Natalizumab for treating unresectable pulmonary osteosarcoma (NCT03811886).
Dr. Kristen VanHeyst completed her medical training at New York Institute of Technology School of Osteopathic Medicine, formally known as New…
playlist_add
Apr 15, 2022
Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
Brooke Bernhardt, PharmD, MS, BCOP, BCPPS is an Assistant Professor in the Department of Pediatrics, Section of Pediatric Hematology/Oncology at Baylor College of Medicine in Houston, Texas and the Director of Pharmacy for Global HOPE (Hematology/Oncology Pediatric Excellence). Her research interests include improving pharmacy practice globally with a focus in Sub-Saharan Africa,…
playlist_add
Apr 15, 2022
A Phase 1/2 Study of ZN-c3 Plus Gemcitabine in Relapsed or Refractory Osteosarcoma
Discussion of a new, early phase clinical trial for patients with metastatic osteosarcoma targeting the DNA damage repair pathway.
Dr. Vishu Avutu attained his M.D. from the University of Texas Southwestern Medical School and began his research endeavors with the Pediatric Oncology Education Program at St. Jude Children’s Research Hospital; finding a passion for working with adolescents and young adults, Vishu matched to the internal medicine-pediatric residency at Harvard’s Brigham and Women’s/Boston Children’s Hospitals. In addition to serving as Chief Resident, Vishu helped develop and launch the Center for Adolescent and Young Adult Oncology at the Dana Farber Cancer Institute. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a co-founder of MSK's Adolescent and Young Adult Oncology Program, where his work has garnered MSK's Patient and Family Centered Care Grant Initiative and the Young Investigator Award from the American…
playlist_add
Apr 1, 2022
MYC Amplification as a Prognostic Biomarker in Osteosarcoma Sponsored by BTG Speciality Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
This talk will focus on research elucidating MYC amplification as the first genomic prognostic biomarker in osteosarcoma, which may be used for risk stratification in future clinical trials and to inform conversations with patients and families. Dr. Marinoff will discuss the tools used to detect MYC amplification, what we have learned about its association with outcome in children…
playlist_add
Mar 25, 2022
Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals
This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
This presentation will explain the process and the challenges of obtaining access to experimental drugs for cancer patients.
Elena is Programs Director at Kids v Cancer, a nonprofit pediatric cancer advocacy organization. Elena directs the Compassionate Use Navigator program, providing guidance and personal assistance to physicians and families in applying for experimental drugs. Previously Elena worked as a science and business journalist, and…
playlist_add
Mar 18, 2022
The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial Sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
Dr. Michelle Ghert is a full Professor in the Department of Surgery, Division of Orthopaedic Surgery at McMaster University. She is Director of MacOrtho Research and co-Chair of the Sarcoma Disease Site at the Juravinski Cancer Center in Hamilton. Dr. Ghert completed her undergraduate and medical degrees at Stanford University and Vanderbilt University respectively. She trained in orthopaedic surgery at Duke University and completed a 2-year f…
playlist_add
Mar 11, 2022
Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
Matteo Trucco, MD is Director Children's Cancer Innovative Therapy Program Associate Staff, Peds Hematology-Oncology & BMT at Cleveland Clinic. He received his training in Pediatric Hematology/Oncology from John's Hopkins and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies.
playlist_add
Mar 4, 2022
Truths & Myths of Nutrition in Cancer sponsored by BTG Specialty Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
With almost 25 years of experience as a registered dietitian nutritionist, Natalie is a well-seasoned practitioner. A board-certified specialist in oncology nutrition, Natalie is the founding dietitian for the nutrition program at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and is the clinical nutrition specialist at Smith Integrative Oncology in San Francisco. On a daily basis, she works with pa…
playlist_add
Feb 25, 2022
Amputation for OS; Patient & Surgeon Perspectives sponsored by BTG Speciality Pharmaceuticals
This episode is sponsored by _BTG Speciality Pharmaceuticals_. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, _Voraxaze_, is for high-dose methotrexate toxicity.
Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sar…
playlist_add
Feb 18, 2022
Surgical Management of Pulmonary Metastases in People with Osteosarcoma - COG Trial
Dr. John Doski, a pediatric surgeon from the UT Health San Antonio will discuss an upcoming randomized trial comparing open and minimally invasive thorascopic surgery for pulmonary metastatic osteosarcoma.
playlist_add
Feb 11, 2022
Human Trial for OST-HER2
Today we talk with Dr. Damon Reed from Moffit Cancer Center and Dr. Nicola Mason from University of Pennsylvania School of Veterinary Medicine about the promising results from a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma, and how that will translate to a human trial. #clinicaltrials #osteosarcoma #cancerupdates
playlist_add
Feb 4, 2022
Osteosarcoma Q&A with Dr. Peter Anderson and OsteoWarriors
In this weeks Osteobites episode Dr. Pete Anderson of Cleveland Clinic, together with OsteoWarriors Andrew, Kara, and Mia, will be asking and answering your questions about Osteosarcoma.
playlist_add
Dec 17, 2021
Osteobites: Back to Activity, Rotationplasty
IIn this weeks Ostoebites episode we chat with Dr. Valerae Lewis & Elise Robinson Rotationplasty and back to activity!
Elise Robinson is 15 years old, an osteosarcoma survivor, MIB Agents Ambassador Agent, and MIB Agents Junior Board member. Elise was diagnosed with osteosarcoma in 2014 when she was eight years old. Elise is active in sports and brings awareness to childhood cancer, osteosarcoma, and amputees with her active lifestyle.
Valerae O. Lewis, M.D. Professor, Orthopaedic Oncology, Division of Surgery Chair, Department of Orthopaedic Oncology, Division of Surgery Dr. John Murray Professor in Orthopaedic Oncology The University of Texas M. D. Anderson Cancer Center Dr. Lewis, the John Murray Professor of Orthopaedic Oncology, attended Yale University and matriculated at Harvard Medical School, graduating with honors. She completed her Orthopaedic training at the Harvard Combined Orthopaedic Residency Program in Boston, MA and her fellowship in Musculoskeleta…
playlist_add
Nov 19, 2021
OsteoBites: Clinical Trials for Relapsed or Refractory Osteosarcoma - The OLIE Study and Beyond!
Join Dr Filemon Dela Cruz & Dr. Julia Glade Bender as they talk about The OLIE Study - Evaluating lenvatinib in combination with chemotherapy for relapsed or refractory osteosarcoma.
......
Organization Memorial Sloan Kettering Cancer Center/MSK Kids
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
LINKS:
OLIE Clinical Trial: LINK
🔗Memorial Sloan Kettering Cancer Center Pediatrics: LINK
📧 Filemon Dela Cruz, MD:…
playlist_add
Nov 12, 2021
Encore, Testing & Research Directory
MIB Agents Osteosarcoma Webinar Series: Alanna Church, MD of Boston Children's and Harvard Medical School and Christina Ip-Toma, MIB Scientific Advisory Board Member and lead of the MIB Testing & Research Directory, talk about navigating the Testing & Research Directory to help inform a personal treatment plan or to inform research.
Christina Ip-Toma, Osteomom, and Alanna Church, MD Pathologist at Dana Farber & Harvard Medical School, worked together with Matteo Trucco, MD, Katie Janeway, MD, Alejandro Sweet-Cordero, MD, Will Parsons, MD, Joshua Schiffman, MD, Ines Lohse, PhD and Al Cornelius, MD to bring the Testing & Research Directory to you as an essential decision-making document.
Guest Information:
Alanna Church, MD is the Associate Director for Molecular Pediatric Pathology Laboratory (LaMPP) Staff Pathologist, Department of Pathology Boston Children's Hospital Assistant Professor of Pathology Harvard Medical School
Christina Ip-Toma is an MIB Agents Scientific A…
playlist_add
Nov 8, 2021
Real Talk: What it's really like and how WE feel about Osteosarcoma.
Osteobites: Junior Board, Like No One is Listening
MIB Junior Board Osteowarriors Ally & Kara, and OsteoSiblings Annika and Valerie have an honest conversation about osteosarcoma. This session is a no-holding-back conversation about unrestricted emotions, real experiences, and new realities.
#likenobodyislistening
...
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours
RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Directory
✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard
...
Kids are still dying with 40+ year old treat…
playlist_add
Oct 22, 2021
Planning for Dignity and What Matters Most to You
Paul Malley is President of Aging with Dignity, a national non-profit organization based in Tallahassee, Florida, with a mission to help individuals and their families receive the care they want in case of a serious illness.
As President of Aging with Dignity, Malley coordinates the national Five Wishes advance care planning program. Created by Jim Towey, founder of Aging with Dignity and former legal counsel to Mother Teresa of Calcutta, Five Wishes is an easy-to-use legal document that addresses important medical issues as well as personal, emotional and spiritual matters at the end of life. More than 35 million Americans have turned to Five Wishes as their preferred tool to make their wishes known and to discuss their preferences with their family and doctor before a health crisis. More than 40,000 partner groups (hospitals, hospices, places of worship, employers, community organizations) make up the growing network of organizations that distribute Five Wishes in communities across…
playlist_add
Sep 24, 2021
Let's Talk Fertility and Osteosarcoma
Dr. Abha Gupta discusses "Fertility Preservation in Osteosarcoma Patients" with Junior Board Members Kara, Valerie, and Alexis. We talk about it ALL.
Dr. Abha Gupta received her MD at the University of Toronto. She completed her pediatrics residency at Yale New Haven Children’s Hospital (New Haven, CT) and Children’s Hospital of Eastern Ontario (Ottawa) before moving back to Toronto to complete her fellowship in pediatric hematology/oncology at The Hospital for Sick Children. To complement her training, Dr. Gupta completed a one-year fellowship in Adolescent and Young Adult Oncology with a focus on sarcoma at Princess Margaret Cancer Centre. She is currently cross-appointed as a staff oncologist at both The Hospital for Sick Children (Solid Tumor Section) and Princess Margaret Cancer Center. She is the Medical Director of the Adolescent and Young Adult Oncology Program at Princess Margaret and Medical Director of the Canadian Sarcoma Research and Clinical Collaboration (…
playlist_add
Sep 17, 2021
How "Hydroxychloroquine and "self-eating" works with Osteosarcoma.
In this weeks Osteobites we join Dr. Andy Livingston & Dr. Nancy Gordon as they share their discussion and leading-edge research about how "Hydroxychloroquine and "self-eating" works with Osteosarcoma." After a short presentation on this research, they take questions from attendees. It's a can't miss Osteobites.
Hosted by: Ann Graham OsteoWarrior and Executive Director of MIB Agents
Youtube Video of this episode: https://youtu.be/OZKi0wxt9ns
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support EDUCATION for physicians, researchers and families:
✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma
✨ MIB Book: Osteosarcoma: From our Families to Yours RESEARCH:
✨ Annual MIB FACTOR Research Conference
✨ Funding $100,000 annually for OS research
✨ MIB Testing & Research Dir…
playlist_add
Sep 12, 2021
Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient
Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient
Dr. Huang is back on OSTEOBites to give us an update on his research funded by OutSmarting Osteosarcoma 2019. Don't miss this exciting new episode, plus who doesn't love Dr. Huang?
* ABOUT Alex Huang, MD, PhD:
Dr. Huang received a B.S. in chemistry and an M.S. in biochemistry and molecular biology from the University of Chicago. He then entered the medical scientist training program at the Johns Hopkins University School of Medicine, where he completed his Ph.D. thesis in the laboratory of Drew M. Pardoll, M.D., Ph.D. Dr. Huang’s Ph.D. thesis included studying the process of in vivo tumor-antigen cross-presentation by bone marrow derived professional antigen presenting cells and identified the dominant MHC class-I restricted tumor rejection antigen, AH-1, in a murine colon tumor model.
Hosted by:
Executive Director of MIB Agents - Ann Graham OsteoWarrior and
MIB Junior Board Member…
playlist_add
Jul 30, 2021
OsteoBites Welcomes Junior Board Members to discuss "Four OsteoWarriors' Perspectives".
OsteoBites Welcomes Junior Board Members to discuss "Four OsteoWarriors' Perspectives".
...
Brandon, Charlotte, Kara, and Maeve will be speaking about their experiences as patients and survivors. Topics include:
📌Life After Osteosarcoma, Brandon Friedman
📌Things I Wish I knew Going Into Treatment, Kara Skrubis
📌What It's Like To Be A Patient On A Clinical Trial, Charlotte Murdoff
📌Connecting After Cancer, Maeve Smart
...
Hosted by: Ann Graham OsteoWarrior and Executive Director of MIB Agents
...
🔗LINKS
Osteosarcoma: www.mibagents.org/outrunning
OS Clinical Trial Search: www.mibagents.org/physicians-researchers/clinical-trials
Ambassador Agents: https://www.mibagents.org/agents/ambassador-agents
…
What We Do at MIB Agents:
PROGRAMS:
✨ End-of-Life MISSIONS
✨ Gamer Agents
✨ Agent Writers
✨ Prayer Agents
✨ Healing Hearts Bereaved Parent Support
✨ Ambassador Agents - Peer Support
EDUCATION for physicians, researchers and famili…
playlist_add
Jul 23, 2021
OsteoBites welcomes Dr. Moyez Jiwa to discuss "The Art of Doctoring"
Dr. Jiwa is a practicing General Practitioner, Editor-in-Chief at the Journal Of Health Design, and an Associate Dean and Professor at the Melbourne Clinical School at the University of Notre Dame.
From Dr. Jiwa: "I bring experience from multiple roles- clinician, researcher, publisher, innovator and leader. What my experience has taught me is that healthcare professionals can achieve great results by focusing on what is in their immediate sphere of influence. In some of my roles, the only thing I got to choose was the color of my tie. Despite that, it has been possible to make a significant contribution to addressing many challenges for patients and providers of healthcare. I enjoy innovating and blogging while practicing the art of medicine."
Hosted by: Ann Graham OsteoWarrior and Executive Director of MIB Agents
Junior Board Members and OsteoWarriors: Mia and Maeve
....
LINKS Dr. Jiwa's Email: moyez.jiwa@nd.edu.au
OutRunning Osteosarcoma: www.mibagents.org/o…
playlist_add
Jun 24, 2021
Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”
MIB Agents Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”
...
Guest Information:
Richard Gorlick, MD
Division Head, Department of Pediatrics
Professor, Department of Pediatrics Patient Care
Director, Department of Pediatric Sarcoma Research Laboratory
Department Chair, ad interim Sarcoma Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center in Houston, TX
Dr. Richard Gorlick is Division Head and Department Chair of Pediatrics, Department Chair ad interim of Sarcoma Medical Oncology in the Division of Cancer Medicine at the MD Anderson Cancer Center, and H. Grant Taylor, M.D., W. W. Sutow, M.D. and Margaret P. Sullivan, M.D. Distinguished Chair in Pediatrics. Dr. Gorlick received his medical degree from Downstate Medical School. He trained at New York-Presbyterian and Memorial Sloan-Kettering Cancer Center, where he began his sarcoma research laboratory and clinica…
playlist_add
Jun 17, 2021
Osteosarcoma OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”
MIB Agents OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”
...
Guest Information:
Lara E. Davis, MD
Associate Professor
Knight Cancer Institute
Co-Leader, Translational Oncology Research Program
Sarcoma Disease Site Leader
Oregon Health & Science University
Lara Davis, MD graduated from Wellesley College and then went on to receive her medical degree from OHSU. After training in a dual Internal Medicine and Pediatrics residency program at Harvard, she returned to Portland to complete a combined Adult and Pediatric Oncology fellowship with a focus on Adolescents and Young Adults (AYAs). Dr. Davis joined the faculty at OHSU in 2013, where she is a member of the Knight Cancer Institute with dual appointments in the Division of Medical Oncology and Pediatric Hematology/Oncology. She focuses exclusively on sarcoma in both the clinic and in the laboratory.
...
Hosted by:
Ann Graham OsteoWarrior and Executive Director of MIB…
playlist_add
Jun 10, 2021
Osteosarcoma OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN on “Nutrition & Cancer; Truths & Myths”
MIB Agents OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN a Registered Dietician who will be sharing her expertise on “Nutrition & Cancer Truths & Myths”
...
Guest Information:
_Julie Lanford, MPH, RD, CSO, LDN__
_Wellness Director, Cancer Services
Julie received her degree in Biology from North Carolina State University and her Masters in public health nutrition from The University of North Carolina at Chapel Hill.
She is a registered dietitian, licensed nutritionist and board-certified specialist in oncology nutrition with 15 years experience. She can be found on her website _CancerDietitian.com_ which translates evidence-based nutrition guidelines for everyday life.
...
Hosted by:
Ann Graham OsteoWarrior and Executive Director of MIB Agents.
…
Next week we will be talking with Dr. Lara Davis, Associate Professor and Sarcoma Program Director at Knight Cancer Institute at Oregon Health & Science University about NEW OSTEOSARCOMA CLINICAL TRIALS!
...
LIN…
playlist_add
May 20, 2021
Osteosarcoma OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM Dana-Farber CI & Harvard Med School “What’s Next? Survivorship"
MIB Agents OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM from Dana-Farber Cancer Institute/Boston Children’s and Harvard Medical School. Dr. Greenzang will be talking about, “What’s Next? Osteosarcoma Survivorship”.
...
Guest Information:
_Katie Greenzang, MD, MpH__
_Pediatric oncologist at Dana-Farber/Boston Children’s Hospital
Instructor at Harvard Medical School
...
Dr. Greenzang completed her pediatrics residency and chief residency at Seattle Children’s Hospital, and her fellowship training in pediatric hematology/oncology at the Dana-Farber Cancer Institute/Boston Children’s Hospital. Her research focuses on patient-provider communication and shared decision-making in children with cancer. She is particularly interested in understanding how families consider the short- and long-term effects of cancer therapies when making treatment decisions, and how we can improve communication about late effects of cancer therapy to help patients and families feel more…
playlist_add
May 13, 2021
Osteosarcoma OsteoBites S2 Ep 14: Lillian Guenther, MD Dana-Farber CI & Harvard Med School “CRISPR Screening to Identify Novel Genomic Targets"
MIB Agents OsteoBites S2 Ep 14: Lillian Guenther, MD from Dana-Farber Cancer Institute and Harvard Medical School. Dr. Guenther will be talking about, “Utilizing CRISPR Screening to Identify Novel Genomic Targets for Osteosarcoma”
....
Guest Information:
Lillian Guenther, MD
_Dana Farber Cancer Institute__
_...
Dr. Guenther received her bachelor degree from Brown University and her MD from SUNY Downstate College of Medicine. She spent one year as a Howard Hughes Medical Institute/NIH Research Scholar studying osteosarcoma in Dr. Lee Helman’s laboratory at the National Cancer Institute. Lily is currently an Instructor in Pediatrics at Harvard Medical School and performs research in the lab of Dr. Kimberly Stegmaier. She cares for pediatric cancer patients at Boston Children’s Hospital and in the Jimmy Fund Clinic at Dana-Farber Cancer Institute. Dr. Guenther was a finalist for our OutSmarting Osteosarcoma Grant. Our group of osteosarcoma families and Scientific Adv…
playlist_add
May 6, 2021
Osteosarcoma OsteoBites S2 E13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”
MIB Agents OsteoBites S2 Ep 13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”
...
Guest Information:
Scott Sauer, PhD
Head of Preclinical Discovery
Vuja De Sciences, Inc. (_www.vujade-life.com_)
...
Dr. Scott Sauer is a cancer researcher with multidisciplinary training in the fields of cancer biology, immunotherapy and organic chemistry. This diverse expertise provides a unique perspective to address unmet medical needs in cancer recurrence and metastasis. Scott received his PhD at Duke University in organic chemistry and a BS from the University of Maryland. After his PhD work, Dr. Sauer began his postdoctoral training at the Duke University Medical Center. His postdoctoral work was in cancer biology focusing on mechanisms of therapeutic resistance and disease progression. During this time, Scott received numerous postdoctoral awards including his work on the interplay between cancer progression and environmental tox…
playlist_add
Apr 29, 2021
Osteosarcoma OsteoBites S2 Ep12: Dan Prince, MD, MPH on “Regenerative Surgery for Bone Sarcomas”
MIB Agents OsteoBites S2 Ep12: Dan Prince, MD on “Regenerative Surgery for Bone Sarcomas”
...
Guest Information:
Daniel Prince, MD, MPH
Orthopedic Surgeon
Memorial Sloan Kettering Cancer
Education (MD): Yale University Medical School
Board Certifications: Orthopedic Surgery
...
Dr. Prince is an Orthopedic Surgeon from Memorial Sloan Kettering Cancer Center on the “MSK Kids” team, specializing in the care of children, adolescents, and young adults with bone tumors and other diseases of the bone. His research and expertise is in bone regeneration, which relies on the body’s natural abilities to regrow bone after a segment of bone is removed during cancer surgery.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
…
What…
playlist_add
Apr 22, 2021
Osteosarcoma OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”
MIB Agents OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”
...
Guest Information:
Ines Lohse, PhD
Assistant Scientist
University of Miami
Center for Therapeutic Innovation
...
Dr. Lohse received her PhD from the University of Zurich in 2011. After postdoctoral fellowships at the Princess Margaret Cancer Center (Toronto) and the University of Michigan, Dr. Lohse moved to the University of Miami to focus on the preclinical and early clinical development of novel technology and therapeutic options for cancer patients. The Ex Vivo Drug Sensitivity Testing Platform has been successfully tested in a pilot cohort of patients, including sarcoma. It is currently in development to transition the platform to clinical routine.
...
Panelists
Mia Sandino, MIB Junior Board Member and OsteoWarrior
Charlotte Murdoff, MIB Junior Board Member and OsteoWarrior
Annika Vallejo, MIB Junior Board Member and OsteoWarrio…
playlist_add
Apr 15, 2021
Osteosarcoma OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
MIB Agents OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
...
Guest Information:
Sumit Gupta, MD, PhD, FRCPC
Hospital for Sick Children, Staff Oncologist and Clinician Investigator
University of Toronto, Associate Professor
Institute for Health Policy, Management and Evaluation, Associate Professor
Cancer Research Program at the Institute for Clinical Evaluative Sciences, Adjunct Scientist
Dr. Gupta completed a PhD in Clinical Epidemiology from the University of Toronto, during which time he was supported by a CIHR Fellowship Award. He is one of the Assistant Chairs of the Lancet Oncology Commission on Sustainable Pediatric Cancer Care in low and middle income countries. Sumit has worked extensively with pediatric oncologists and policymakers throughout Latin America, the Caribbean, and India. He currently holds grant funding from The Garron Family Cancer Centre, CIHR and the Terry Fox Resear…
playlist_add
Apr 8, 2021
MIB Agents OsteoBites S2 Ep 9: Jane Yanagawa, MD, “Osteosarcoma Lung Metastases”
MIB Agents OsteoBites S2 Ep 9: Jane Yanagawa, MD, “Osteosarcoma Lung Metastases”
Guest Information:
Jane Yanagawa, MD
Associate Professor of Thoracic Surgery,
UCLA David Geffen School of Medicine, Department of Surgery
...
Dr. Yanagawa is a thoracic surgeon at the UCLA David Geffen School of Medicine, Department of Surgery. She completed her residency at UCSD and her fellowship in Thoracic Surgery at Memorial Sloan-Kettering Cancer Center.
...
Our panel today includes Amy Woodcheke, Physicians Assistant and Childhood Cancer Survivor. And MIB Junior Board Members and OsteoWarriors Mia Sandino and Charlotte Murdoff. I am your host, Ann Graham Executive Director of MIB Agents.
...
Coming up next week is Sumit Gupta, MD, PhD who will be speaking on “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our
community of patients, caregivers, do…
playlist_add
Apr 1, 2021
OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”
MIB Agents OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”
Guest Information:
Chand Khanna DVM, PhD
Chief Science Officer, Ethos Veterinary Health
President, President of Ethos Discovery
Dr. Khanna is a well known osteosarcoma expert and researcher. He is a board-certified diplomate of the American College of Veterinary Internal Medicine (Oncology) and an honorary Diplomate of the American College Veterinary Pathology. He received a PhD in Pathobiology from the University of Minnesota and then completed a postdoctoral fellowship in the Pediatric Oncology Branch of the National Cancer Institute where he led a laboratory focused on metastasis drug discovery and was the founding director of the NCI Comparative Oncology Program. Dr. Khanna is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery, a nonprofit incubator of scientific innovation.
...
Our panel today includes Amy Woodchecke BS,…
playlist_add
Mar 5, 2021
OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”
MIB Agents OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”
Guest Information:
Corrie Painter, PhD
Deputy Director, Count Me In. OSProject.org
Broad Institute of MIT & Harvard
Corrie Painter, PhD is the Associate Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies. She is also the co-founder of Angiosarcoma Awareness Inc.
...
Our panel today includes 2021 MIB Junior Board Member Shannon McCormack, 2020 Junior Board Member Ryan Kennington and Amy Woodchecke BS, MHS, PA-C,, a childhood cancer survivor and pediatric oncology Physician’s Assistant…
playlist_add
Feb 11, 2021
OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”
MIB Agents OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”
Guest Information:
Brian Van Tine, M.D., Ph.D.
Associate Professor of Medicine
Associate Professor of Pediatrics
Washington University in St Louis, Missouri
Sarcoma Program Director
Co-Director of the Adolescence and Young Adult Program
Alvin J. Siteman Cancer Center.
Dr. Van Tine has been the head of the Sarcoma Clinical Trials Program at Washington University for the past decade. Dr. Van Tine’s laboratory is dedicated to understanding the metabolism of sarcoma, and has recently developed a dual metabolic therapy for the treatment of complex cytogenetic sarcomas based on the exploitation of argininosuccinate synthetase 1 deficiency and glutaminase inhibition.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a c…
playlist_add
Feb 4, 2021
OsteoBites S2 Ep5: Robbie Majzner, MD on “Unleashing the Pediatric Immune System Against Osteosarcoma and Other Solid Tumors”
MIB Agents OsteoBites S2 Ep5: Robbie Majzner, MD on “Unleashing the Pediatric Immune System Against Osteosarcoma and Other Solid Tumors”
Guest Information:
Robbie Majzner, MD
Assistant Professor of Pediatrics
Stanford University School of Medicine
...
Dr. Majzner is an Assistant Professor of Pediatrics at Stanford University School of Medicine. After graduating with a BA from Columbia University, he attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency at NY Presbyterian-Columbia and fellowship in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on developing immunotherapies for children with incurable solid tumor cancers. His laboratory work aims…
playlist_add
Jan 29, 2021
OsteoBites S3 Ep4: Lor Randall, MD, "Sarcomatology: A Trans-Disciplinary Approach"
MIB Agents OsteoBites S3 Ep4: Lor Randall, MD, Sarcomatology: A Trans-Disciplinary Approach
Guest Information:
R. Lor Randall, MD, FACS
Professor & Chair, University of California, Davis
David Linn Endowed Chair in Orthopaedic Surgery.
Dr. Randall’s clinical practice and research focus on musculoskeletal surgical oncology and on building leading-edge, trans-disciplinary teams to combat rare cancers of connective tissue in children and adults. His translational research efforts have been recognized internationally. He is also responsible for the development of the Sarcoma Advanced Research and Clinical (SARC) Fellowship, one of the most sought-after clinical training experiences in the world.
Dr. Randall has authored innumerable peer-reviewed articles, book chapters and abstracts in the field of sarcoma surgery and biology. He has received numerous national and international awards and has helped develop Adolescent and Young Adult Cancer Care Programs at Utah and UC Davis.…
playlist_add
Jan 21, 2021
OsteoBites S2 Ep3: Pete Anderson, MD, PhD "Understanding Lab, Path and Scan Reports and Other Questions Answered"
MIB Agents OsteoBites S2 Ep3: Pete Anderson, MD, PhD of Cleveland Clinic Understanding Lab, Path and Scan Reports and Other Questions Answered.
Guest Information:
Dr. Pete Anderson is an MIB Agents Board Member and MIB Scientific Advisory Board Member. He is a professor and practices pediatric hematology oncology at Cleveland Clinic. He has also practiced at University of Texas MD Anderson Cancer Center, where he was section chief of non-neural solid tumors, and Mayo Clinic, where he launched the pediatric bone marrow transplant program. He received his Medical degree from Mount Sinai School of Medicine. Residency in both internal medicine and pediatrics at Duke; fellowship in pediatric hematology-oncology at University of Minnesota
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive b…
playlist_add
Jan 14, 2021
OsteoBites S2 Ep2: Alejandro Sweet Cordero, MD "Genome-Informed Targeted Therapies for Osteosarcoma"
MIB Agents OsteoBites S2 Ep2: Alejandro Sweet Cordero, MD on Genome-Informed Targeted Therapies for Osteosarcoma.
Guest Information:
Alejandro Sweet-Cordero, MD is a physician-scientist focused on basic and translational sarcoma biology. His interest is in mechanisms driving osteosarcoma and Ewing sarcoma progression, metastasis and therapy resistance. They use patient-derived xenografts and direct analysis of patient tumors as tools for gene discovery. The Sweet-Cordero Lab has expertise in integrative genomic analysis and extensive experience in generating next-generation sequencing datasets for gene and network discovery using both primary tumors and human and mouse model systems.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org…
playlist_add
Jan 8, 2021
OsteoBites S2 Ep1: Erin Murphy, Associate Professor, Radiation Oncology at Cleveland Clinic: Radiosurgery and SBRT for Sarcoma”
MIB Agents OsteoBites S2 Ep1: Erin Murphy, Associate Professor, Radiation Oncology at Cleveland Clinic: Radiosurgery and SBRT for Sarcoma”.
Guest Information:
Erin S. Murphy MD is an Associate Professor in the department of radiation oncology at the Cleveland Clinic. She completed residency at the Cleveland Clinic and a fellowship in pediatric radiation oncology at St. Jude Children’s Research Hospital. She specializes in radiotherapy and radiosurgery for brain tumors and pediatric tumors and has given many presentations and has multiple publications on these topics.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of p…
playlist_add
Nov 21, 2020
OsteoBites S1 Ep28: Ryan Roberts, MD, PhD. “Dear Lungs, Stop enabling this cancer: Targeting interactions that facilitate osteosarcoma metastasis.”
MIB Agents OsteoBites S1 Ep28: Ryan Roberts, MD, PhD. “Dear Lungs, Stop enabling this cancer: Targeting interactions that facilitate osteosarcoma metastasis.”
Guest Information:
Ryan D. Roberts, MD, PhD
Division of Hematology and Oncology-Nationwide Children’s Hospital
Center for Childhood Cancer and Blood Diseases-Wexner Research Institute at Nationwide Children’s
Translational Therapeutics Program-The James Comprehensive Cancer Center, Ohio State University.
...
His research seeks to understand the mechanisms that support lung metastasis development in osteosarcoma. We focus on the interactions between tumor cells and lung cells, between tumor cells and immune cells, and between individual tumor cells that exhibit distinct types of behavior. By manipulating these interactions using well-tolerated agents, we hope to make the tumor cells much less comfortable in the lung—preventing metastases from forming and rendering resistant tumors treatable.
...
MIB Agents is a…
playlist_add
Nov 15, 2020
OsteoBites S1 Ep27: Brian Crompton, MD, “New Genomic Approaches to Understanding Osteosarcoma”
OsteoBites S1 Ep27: Brian Crompton, MD, “New Genomic Approaches to Understanding Osteosarcoma”
...
Brian D. Crompton, MD
Assistant Professor of Pediatrics
Department of Pediatric Oncology
Dana-Farber Cancer Institute
...
Dr. Crompton’s research focuses on utilizing genomic and proteomic technologies to identify and validate new therapeutic targets for pediatric solid tumors and to develop non-invasive biomarkers of treatment response and resistance in these diseases. We have recently developed a new approach to study tumor genomics through liquid biopsy technologies including the profiling of circulating tumor DNA and circulating tumor cells in blood samples of patients with pediatric solid tumors. Dr. Crompton is also engaged in national efforts to study the biology of osteosarcoma through the Children’s Oncology Group studies and through patient-led research initiatives including the Count Me In project.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit d…
playlist_add
Oct 16, 2020
OsteoBites S1 Ep25: Sulagna Banerjee, PhD, “Modeling Osteosarcoma in Mice”
MIB Agents OsteoBites S1 Ep25: Sulagna Banerjee, PhD, “Modeling Osteosarcoma in Mice”
Guest Information:
*Sulagna Banerjee, PhD
Research Scientist, University of Miami Health System
Sulagna Banerjee Laboratory
Associate Professor, University of Miami’s Miller School of Medicine.
...
Hosted By Ann Graham, OsteoWarrior & MIB Agents President
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Next week, OsteoBites welcome Dr. Jin-Ah Kim of Children’s Cancer Therapy Development Institute. Dr. Kim will be speaking about “Reversing Checkpoint Adaptation: Making Osteosarcoma Treatments Work Better.”
...
Register: https://bit.ly/MIBobites
playlist_add
Sep 24, 2020
OsteoBites S1 Ep24: Andy Woods & Charles Keller, MD: "Legacy Autopsy”
MIB Agents OsteoBites S1 Ep24: Andy Woods & Charles Keller, MD: "Legacy Autopsy”
Guest Information:
*Andy Woods, BS
Senior Research Scientist & Childhood Cancer Dad
Children’s Cancer Therapy Development Institute (cc-TDI)
*Charles Keller, MD
Scientific Director
Children’s Cancer Therapy Development Institute (cc-TDI)
...
Panelists Information:
* Shannon McCormick, MIB Ambassador Agent, OsteoWarrior Sibling
* Amanda Levine, OsteoWarrior, Patient Advocate
* Hosted By Ann Graham, OsteoWarrior & MIB Agents President
...
Next week OsteoBites takes a break.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Register: _https://bit.ly/MIBobites_
playlist_add
Sep 21, 2020
Lauren: Osteosarcoma Survivor, Sibling of OsteoAngel and MIB Jr. Board Member
Lauren: Osteosarcoma Survivor, Sibling of OsteoAngel and MIB Jr. Board Member
Each week we feature a survivor of Osteosarcoma on #SurvivorSaturday. This week, we shared a video from our annual MIB FACTOR 2020 Osteosarcoma Conference. Lauren closed out our conference by sharing hers and her family's story of fighting this disease.
Lauren, an MIB Agent Jr Board Member, had us crying, cheering and on our feet clapping at FACTOR 20. Her story of survivorship, loss, gratitude and grace is inspiring and humbling.
...
More Hope: https://bit.ly/MIBhope
...
Video Production: Maggie Scanlon
playlist_add
Sep 18, 2020
OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma ”
MIB Agents OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma”
...
Guest Information:
*Brian Flesner, DVM, MS, DACVIM
American College of Veterinary Internal Medicine (ACVIM)
Assistant Professor of Oncology
College of Veterinary Medicine at the University of Missouri
...
In addition to studying #osteosarcoma, Dr. Flesner’s research interests include chemotherapy mechanisms of action and toxicity, cancer-induced pain, and novel chemotherapeutic approaches to combat aggressive neoplasms. Extensively involved in the vibrant clinical trials service at the MU Veterinary Health Center. The trials service sees hundreds of patients annually; notably, 70 dogs with osteosarcoma were enrolled in osteosarcoma specific clinical trials in the past four years. Dr. Flesner is currently site principal-investigator for several ongoing osteosarcoma studies, including three near completion National Cancer Institute COTC nationwide trials.
...…
playlist_add
Sep 10, 2020
OsteoBites S1 Ep22: Reed: "Moffitt Osteosarcoma Research Approach”
MIB Agents OsteoBites S1 Ep22: Damon Reed, MD: "Moffitt Osteosarcoma Research Approach ”
Guest Information:
*Damon Reed, MD
Moffitt Cancer Center
Director, Adolescent Young Adult Program
Interim Chair of the Dept of of Individualized Cancer Mgmt
Asst Professor of Pediatrics, University of South Florida.
MIB Agents Scientific Advisory Team
Panelists Information:
Amanda Levine, OsteoWarrior & Patient Advocate
Ryan Kennington, OsteoWarriors & MIB Junior Board Member
Hosted By Ann Graham, OsteoWarrior & MIB Agents President
...
Next week OsteoBites talks with Dr. Brian Flesner of University of Missouri about Adjuvant Chemotherapy for Canine Osteosarcoma, and September 24th Dr. Charles Keller and Andy Woods talk about the After-Life Gift of Legacy Tissue Donation.
...
MIB Agents is a leading pediatric _#osteosarcoma_ nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatm…
playlist_add
Aug 27, 2020
OsteoBites S1 Ep21: Kurt Weiss, MD, A Day In the Life of a Musculoskeletal Oncologist
MIB Agents OsteoBites S1 Ep21: Weiss: "A Day In the Life of a Musculoskeletal Oncologist”
...
Guest Information: *Kurt Weiss, MD
OsteoWarrior
Associate Professor University of Pittsburgh, School of Medicine
Department of Orthopaedic Surgery, Division of Musculoskeletal Oncology
Vice Chair of Translational Research
Director Musculoskeletal Oncology Laboratory
Panelists are:
*Maeve Smart OsteoWarrior & MIB Junior Board Member
*Ryan Kennington Hosted By Ann Graham OsteoWarrior & MIB Junior Board Member
*Hosted by: Ann Graham, OsteoWarrior & MIB Agents President
...
Next week OsteoBites takes a break in honor of Labor Day.
Childhood Cancer Awareness Month, also known as September, has three great speakers starting on September 10th with Dr. Damon Reed, September 17th with Dr. Brian Flesner and September 24th Dr. Charles Keller.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients,…
playlist_add
Aug 21, 2020
OsteoBites S1 Ep20: Correlative Science Leading to Active and Emerging Clinical Trials for #Osteosarcoma
MIB Agents OsteoBites S1 Ep20: Correlative Science Leading to Active and Emerging Clinical Trials for #Osteosarcoma
...
Guest Information:
*Richard Gorlick, MD
Division Head, Dept Chair and Professor Pediatrics
Director of the Pediatric Sarcoma Research Lab
The University of Texas, MD Anderson Cancer Center
*J. Andrew Livingston, MD
Assistant Professor, Department of Sarcoma Medical Oncology
Department of Pediatrics
Co-leader for the MDACC Adolescent and Young Adult Program
University of Texas MD Anderson Cancer Center
*Sajad Khazal, MB. ChB.
Assistant Professor, Department of Pediatrics
Patient Care Division of Pediatrics
The University of Texas MD Anderson Cancer Center
Panelists:
*Charlotte Murdoff
OsteoWarrior & MIB Fund Holder
*Ryan Kennington
OsteoWarrior & MIB Agents Junior Board Member
*Amanda Levine
OsteoWarrior & Patient Advocate
Hosted By Ann Graham, MIB Agents President
...
Register for next week when we will be speaking with:…
playlist_add
Aug 14, 2020
OsteoBites S1 Ep19: Modeling & Targeting MYC-Driven Osteosarcoma
MIB Agents OsteoBites S1 Ep19: Modeling & Targeting MYC-Driven #Osteosarcoma with Jason Yustein, MD, PhD
Guest Information:
Jason Yustein, MD, PhD
Texas Children’s Hospital
Associate Professor, Department of PediatricsHematology/Oncology
Baylor College of Medicine
…
Hosted by Ann Graham MIB Agents Founder & President.
…
Register for next week when we will be speaking with
Richard Gorlick, MD
Division Head and Department Chair
University of Texas, MD Anderson Cancer Center
“Correlative Science Leading to Active and Emerging Clinical Trials”.
Register: _https://bit.ly/MIBobites_
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our
community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
...
Osteosarcoma, Bone Cancer, Sarcoma, Pediatric Cancer, Childhood Cancer, Cancer, Cancer…
playlist_add
Aug 10, 2020
OsteoBites S1 Ep18: Coping Through Cancer: Tips for Parents & Caregivers
MIB Agents OsteoBites S1 Ep18: Coping Through Cancer: Tips for Parents & Caregivers
...
Guest Information:
*Lori Wiener, PhD
Co-Director, Behavioral Health Core
Director, Psychosocial Support and Research Program
Pediatric Oncology Branch, Center for Cancer Research
National Cancer Institute & National Institutes of Health
*Amanda Thompson, PhD
Chief, Pediatric Psychology
Life with Cancer
Inova Schar Cancer Institute
Inova Health System
…
Hosted by Ann Graham
MIB Agents Founder & President.
…
Register for next week when we will be speaking with Jason Yustein, MD, PhD of Texas Children’s Hospital Associate Professor, Department of PediatricsHematology/Oncology Baylor College of Medicine On “Modeling and Targeting MYC-Driven OS”. Register: https://bit.ly/MIBobites
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of…
playlist_add
Jul 30, 2020
OsteoBites S1 Ep17: The #Osteosarcoma Patient Decision Aid for Surgical Options in the Lower Extremity
MIB Agents OsteoBites S1 Ep17: The Osteosarcoma Patient Decision Aid for Surgical Options in the Lower Extremity with Janet Panoch, PhD of Indiana University
...
Guest Information:
*Janet Panoch, PhD
Assistant Research Professor
Department of Pediatrics
Indiana University School of Medicine
...
Panelists:
Sloane Dyer, MIB Agents Jr. Board Member & OsteoWarrior
Maeve Smart, MIB Agents Jr. Board Member & OsteoWarrior
Amanda Braunfeld Levine, OsteoWarrior and the founder FaceBook Group for #osteosarcoma and a Patient Advocate
Hosted by Ann Graham MIB Agents Founder & President
...
Register for next week when we will be speaking with Dr. Lori Weiner, co-director of the Behavioral Health Core and Head of the Psychosocial Support and Research Program of the NCI’s Center for Cancer Research. AND Dr. Amanda Thompson, Chief of Pediatric Psychology at INOVA Life With Cancer Program.“Coping Through Cancer”
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicat…
playlist_add
Jul 23, 2020
OsteoBites S1 Ep16: Peter Anderson, MD, PhD on Making It Better for OS Patients
MIB Agents OsteoBites S1 Ep16: Peter Anderson, MD, PhD on Making It Better for Osteosarcoma Patients
...
Guest Information:
Peter Anderson, MD, PhD
Pediatric Hematology Oncology and Blood and Marrow Transplantation
Cleveland Clinic
Cleveland, Ohio
...
Panelists:
Maeve Smart, MIB Agents Jr. Board Member, OsteoWarrior
Sloane Dyer, MIB Agents Jr. Board Member, OsteoWarrior
Amanda Braunfeld Levine, OsteoWarrior, Founder of FaceBook Group for #osteosarcoma and a Patient Advocate
Hosted by Ann Graham MIB Agents Founder & President.
…
Register for next week when we will be speaking with Dr. Janet Panoch of Indiana University on the Osteosarcoma Patient Decision Aid for Surgical Options in the Lower Extremity.
...
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More inform…
playlist_add
Jul 17, 2020
OsteoBites S1 Ep15: Survivorship Care Planning with David Poplack, MD and Ellen Shohet, RN
Survivorship Care Planning with David Poplack, MD and Ellen Shohet, RN with Passport For Care, an interactive website that addresses the need to provide long-term survivors of #ChildhoodCancer and their caregivers with screening guidelines and resources individualized to the survivor’s treatment history.
...
Guest Information:
*Ellen Shohet, MN, RN
Nurse Navigator, Passport For Care
Baylor College of Medicine
Texas Children's Hospital
*David Poplack, MD
Director of Texas Children's Hospital Cancer and Hematology Centers for 25 years.
Associate Director of the Cancer and Hematology Centers
Director of Global Hematology-Oncology Pediatric Excellence (HOPE)
Developer of the Passport for Care®.
...
Panelists:
Alexis Johnson, OsteoWarrior
MIB Agents Jr. Board Member
MIB Mission Commander
Amanda Braunfeld Levine, OsteoWarrior
Founder- FaceBook Group for #osteosarcoma
Patient Advocate
Hosted by Ann Graham
MIB Agents Founder & President.
…
Register for nex…
playlist_add
Jul 10, 2020
OsteoBites S1 Ep14 Katie Janeway, MD, NEW Osteosarcoma Clinical Trial
NEW CLINICAL TRIAL FOR #OSTEOSARCOMA ANNOUNCED!
MIB Agents Osteosarcoma Webinar Series: Katherine A. Janeway, MD, and Suzanne Forrest, MD discuss the opening of a new clinical trial for osteosarcoma, funded by Osteosarcoma Institute. Updates on the OSProject as well! TRIAL LINK
...
Guest Information:
*Katherine A. Janeway, MD, MMSc
Associate Professor of Pediatrics, HMX - Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute/Boston Children's Hospitals Cancer & Blood Disorders Center
Director, Clinical Genomics, Dana-Farber Cancer Institute
*Suzanne Forrest, MD
Instructor of Pediatrics, Harvard Medical School Pediatric Hematology/Oncology,
Dana-Farber Cancer Institute, Boston Children's Cancer & Blood Disorders
...
All OsteoWarrior Panelists are;
*Maeve Smart
is an MIB Agents Jr. Board Member and and OsteoWarrior
*Alexis Johnson
is an MIB Agents Jr. Board Member and MIB Mission Commander
*Amanda Braunfeld Levine
is a Patien…
playlist_add
Jul 2, 2020
OsteoBites S1 Ep12: John Healey, MD, Precision Surgery for Osteosarcoma
MIB Agents #Osteosarcoma Alliance Webinar Series: John Healey, MD, FACS talks with us about Precision Surgery for osteosarcoma and answers questions from callers and panelists. This session is powerful, informative and even entertaining. We are so grateful for Dr. Healey's expertise and care of this community of patients. He is a brilliant and careful surgeon and an important part of MIB Agents.
...
Guest Information:
John Healey, MD, FACS
Chief of Orthopedic Surgery
Memorial Sloan Kettering Cancer Center
MIB Agents Board of Directors
MIB Agents Scientific Advisory Team
Contributor, "Osteosarcoma: From Our Family to Yours" Book
...
Panelists:
Lauren Ramer is an MIB Agents Jr. Board Member, OsteoWarrior and sibling to OsteoAngel Brother, Brent.
Andrew Bisaga is an MIB Agents Jr. Board Member and OsteoWarrior
Amanda Levine is the founder and manager of the Closed FaceBook Group for osteosarcoma and a Patient Advocate
Liz Vallejo is MIB Agents Programs Chief and Mom…
playlist_add
Jun 18, 2020
OsteoBites S1 Ep11: Alanna Church, MD and Christina Ip-Toma, MIB Testing & Research Directory
MIB Agents Osteosarcoma Webinar Series: Alanna Church, MD of Boston Children's and Harvard Medical School and Christina Ip-Toma MIB Testing Research Directory Lead talk about navigating the Testing & Research Directory to help inform a personal treatment plan or to inform research. Christina Ip-Toma, MIB OsteoWarrior Parent and Alanna Church, MD Pathologist at Dana Farber & Harvard Medical School worked together with Matteo Trucco, MD, Katie Janeway, MD, Alejandro Sweet-Cordero, MD, Will Parsons, MD, Joshua Schiffman, MD, Ines Lohse, PhD and Al Cornelius, MD to bring this important document to you as an essential decision-making document. OsteoParents Karen Davis and Caroline Rothermel Adams contributed early work to bring about this work.
...
Guest Information:
Alanna Church, MD is the Associate Director for Molecular Pediatric Pathology Laboratory (LaMPP)
Staff Pathologist, Department of Pathology
Boston Children's Hospital
Assistant Professor of Pathology
Harvard Medical…
playlist_add
Jun 12, 2020
OsteoBites S1 Ep10: Simon Holland and Elly App
MIB Agents Osteosarcoma Webinar Series: Simon Holland, Co-Founder of Elly Health shares Elly Health -an app that provides support and comfort for those in treatment for cancer
...
Guest Information:
*Simon Holland spent his childhood between Peru, Australia and Spain, and was exposed to a diverse array of people, places and culture. Bringing these eclectic experiences into adulthood, he studied Entrepreneurship at RMIT in Melbourne. Simon has applied his knowledge of design, strategic thinking and defining a clear purpose to over 50 startups. He believes the entrepreneurial struggle is an opportunity for innovative thinking. He used this passion to help fledgling startups grow and find a product-market fit. Simon co-founded HotDoc, Australia’s largest patient engagement platform used by almost 5 millions patients, as well as Vivi which is a screen mirroring solution for education. In 2019 Simon moved to Los Angeles to co-found Elly, an empathetic audio companion for pati…
playlist_add
Jun 4, 2020
OsteoBites S1 Ep9: Amputee Coalition
MIB Agents Osteosarcoma Webinar Series: Tonya Osborne-Simpson and Nicole Gross of Amputee Coalition share programs and resources and discuss the partnership with MIB Agents.
...
Guest Information:
*Tonya Osborne-Simpson, Director of Support & Outreach and Certified Master Trainer oversees the Peer Support department and the National Limb Loss Resource Center.
*Nicole Gross is the Peer Support Programs Manager. Nicole joined the Amputee Coalition in January 2018 with both personal and professional experience in supporting the limb loss and limb difference community as a former adaptive swim and para-triathlon coach and 2013 Boston Marathon Bombing survivor. After her traumatic above knee amputation, Nicole’s sister and Mom became Certified Peer Visitors to help others along their journey. As Peer Support Programs Manager, Nicole oversees the Amputee Coalition’s nationally recognized Certified Peer Visitor Program, Support Group Network, and Hospital Partnership Program. She is…
playlist_add
May 28, 2020
OsteoBites S1 Ep8: Osteosarcoma Research, Joshua Schiffman, MD
MIB Agents Osteosarcoma Webinar Series:
Dr. Joshua Schiffman shares an update on his osteosarcoma research, funded by MIB Agents: "EP53 Loaded Nanoparticles for Osteosarcoma". After a presentation on this research, Dr. Schiffman answers questions from attendees.
...
Guest Information: Joshua Schiffman, MD
Medical Director, Family Cancer Assessment Clinic
Professor of Pediatrics (Hematology/Oncology)
Adjunct Professor of Oncological Sciences
Investigator, Huntsman Cancer Institute
University of Utah
...
OsteoBites Panelist is Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma". Hosted by Ann Graham, President of MIB Agents.
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer.
More information at www.mibage…
playlist_add
May 23, 2020
OsteoBites S1 Ep7: Osteosarcoma Research, Matteo Trucco, MD
MIB Agents Osteosarcoma Webinar Series: Dr. Matteo Trucco shares an update on his osteosarcoma research, funded by MIB Agents: "Disulfiram to Overcome Chemo Resistance". After a presentation on this research, Dr. Trucco answers questions from attendees.
...
Guest Information: Matteo Trucco, MD
Director Children's Cancer Innovative Therapy Program
Associate Staff, Peds Hematology-Oncology & BMT
Cleveland Clinic Children's
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group" and Liz Vallejo, MIB Agents Program Chief. Hosted by Ann Graham, President of MIB Agents. MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a…
playlist_add
May 14, 2020
OsteoBites S1 Ep6: Osteosarcoma Research, J. Andrew Livingston, MD
MIB Agents Osteosarcoma Webinar Series OsteoBites
Dr. Andrew Livingston shares an update on his osteosarcoma research, funded by MIB Agents: "CD73 The Next Immunotherapy Target for OS". After a presentation on this research, Dr. Livingston answers questions from attendees.
...
Guest Information: J. Andrew Livingston, MD
Assistant Professor, Department of Sarcoma Medical Oncology
Department of Pediatrics Co-leader for the MDACC Adolescent and Young Adult Program
University of Texas MD Anderson Cancer Center
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group". Hosted by Ann Graham, President of MIB Agents.
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the g…
playlist_add
May 8, 2020
OsteoBites S1 Ep5: Osteosarcoma Research, Alex Huang, MD, PhD of UH Rainbow Babies & Children's & CWRU
MIB Agents Osteosarcoma Webinar Series: Dr. Alex Huang shares an update on his osteosarcoma research, funded by MIB Agents: "Conditioning the Immune Environment for Effective Therapies for Metastatic OS". After a presentation on this research, Dr. Huang answers questions from attendees.
...
Guest Information:
Alex Huang, MD, PhD
Website: www.huanglab.com
Theresa G. & Stuart F. Kline Family Foundation Chair in Pediatric Oncology
Professor of Pediatrics, Pathology, Biomedical Engineering and General Medical Sciences
Case Western Reserve University School of Medicine
Director, Pediatric Hematology-Oncology Fellowship Program
UH Rainbow Babies & Children's Hospital
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group". Hosted by Ann Graham, President of MIB Agents. MIB Agents…
playlist_add
May 6, 2020
OsteoBites S1 EP2: Osteosarcoma Q&A with Matteo Trucco, MD of Cleveland Clinic
MIB Agents OsteoBites welcomes Matteo Trucco, MD of Cleveland Clinic. He answers general osteosarcoma questions.
...
Guest Information:
Matteo Trucco, MD
Director Children's Cancer Innovative Therapy Program
Associate Staff, Peds Hematology-Oncology & BMT
Cleveland Clinic Children's
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group". Hosted by Ann Graham, President of MIB Agents.
...
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
playlist_add
May 2, 2020
OsteoBites S1 Ep4: Upfront Surgery for Osteosarcoma, David Loeb, MD, PhD & Matteo Trucco, MD
MIB Agents Osteosarcoma Webinar Series: Grab a snack and sit down with Dr. Loeb and Dr. Trucco to talk about and vote on a possible clinical trial on Upfront Surgery for Osteosarcoma. YOU can help inform osteosarcoma research! After the presentation on this research, Dr. Loeb & Dr. Trucco answer questions from attendees.
...
Guest Information:
David Loeb, MD, PhD
Chief, Division of Pediatric Hematology, Oncology, and Marrow & Blood Cell Transplantation
Children's Hospital at Montefiore
Professor, Pediatrics Developmental and Molecular Biology
Albert Einstein College of Medicine
Matteo Trucco, MD
Director Children's Cancer Innovative Therapy Program
Associate Staff, Peds Hematology-Oncology & BMT
Cleveland Clinic Children's
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support G…
playlist_add
Apr 27, 2020
OsteoBites: S1, EP3 Osteosarcoma Institute with Lee Helman, MD & Joyce Schaffer, RN
MIB Agents Osteosarcoma Webinar Series: Lee Helman, MD of the Osteosarcoma Institute and Joyce Shaffer, RN of Osteosarcoma Institute, (OS Institute). The OS Institute is committed to osteosarcoma research and service to the OS community. Dr. Helman and Joyce talk about the incredible free resource, the Osteosarcoma Hotline and osteosarcoma in general. OSTEOSARCOMA HOTLINE: 833-801-3435
...
Guest Information:
Lee Helman, MD
Director, Osteosarcoma Institute (Osinst.org)
Adjunct Clinical Professor of Pediatrics
Cancer and Blood Disease Institute CHLA
Keck School of Medicine, USC
...
OsteoBites Panelists are Amanda Braunfeld Levine of the closed FB group "Bone Cancer Support...for lives touched by Osteosarcoma & Ewing Sarcoma" and Florencia Pistritto of the Facebook Group "Osteosarcoma and Ewing's Sarcoma Support Group". Hosted by Ann Graham, President of MIB Agents.
...
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our…
playlist_add